ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older. ENBREL is indicated for ...
SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older. ENBREL is indicated for ...
THOUSAND OAKS, Calif., and RADNOR, Penn., – Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker. Amgen announced the availability of ...
DUBLIN--(BUSINESS WIRE)--The "Enbrel - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Enbrel Drug Insight, 2019 highlights the drug marketed details and the Global API ...
Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...
March 18, 2008 — A black box warning has been issued for etanercept (Enbrel, manufactured by Immunex Corporation; marketed by Amgen and Wyeth Pharmaceuticals) regarding the risk for tuberculosis and ...
THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...
THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results